Loading...
XLON
FARN
Market cap305mUSD
Apr 07, Last price  
215.00GBP
1D
0.00%
1Q
7.50%
Jan 2017
-18.85%
IPO
-22.51%
Name

Faron Pharmaceuticals Oy

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-70.49%
Rev. gr., 5y
-61.50%
Revenues
0k
0200,000906,000520,0001,153,0001,49519,00000000
Net income
-31m
L+3.03%
-2,460,000-1,508,000-1,364,000-6,188,000-9,294,000-21,060,000-20,086,000-13,262,000-16,946,000-21,194,000-30,034,000-30,944,000
CFO
-23m
L-3.51%
-2,268,000-768,000-389,000-7,146,000-8,452,000-18,363,000-20,525,000-11,523,000-17,479,000-22,218,000-22,993,000-23,806,000-22,971,000
Earnings
Aug 25, 2025

Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
URL
https://www.faron.com/
IPO date
Nov 17, 2015
Employees
40
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
28,594
28,228
Unusual Expense (Income)
NOPBT
(28,594)
(28,228)
NOPBT Margin
Operating Taxes
1,304
Tax Rate
NOPAT
(28,594)
(29,532)
Net income
(30,944)
3.03%
(30,034)
41.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,850
26,031
13,445
BB yield
-12,407.15%
-8.84%
Debt
Debt current
3,839
3,638
2,004
Long-term debt
8,577
9,686
11,581
Deferred revenue
Other long-term liabilities
3,838
896
1,011
Net debt
2,913
6,449
6,595
Cash flow
Cash from operating activities
(22,971)
(23,806)
(22,993)
CAPEX
(1,000)
(123)
(385)
Cash from investing activities
(226)
(123)
(385)
Cash from financing activities
25,816
23,983
23,478
FCF
(2,600)
(27,443)
(28,174)
Balance
Cash
9,503
6,875
6,990
Long term investments
Excess cash
9,503
6,875
6,990
Stockholders' equity
(194,730)
(169,363)
(140,892)
Invested Capital
200,919
168,209
143,696
ROIC
ROCE
2,477.82%
EV
Common stock shares outstanding
69
50,724
Price
2.05
-32.79%
3.05
1.67%
3.00
12.15%
Market cap
210
-99.86%
152,172
12.15%
EV
6,659
158,767
EBITDA
315
(28,248)
(27,928)
EV/EBITDA
Interest
1,400
Interest/NOPBT